CSRxP: BIDEN ADMINISTRATION TAKES IMPORTANT STEP TO PROTECT SENIORS & TAXPAYERS WITH DELAY OF REBATE RULE

HHS Pause of Misguided, Pharma-Backed Policy Will Help Refocus Attention on Holding Big Pharma Accountable in Order to Lower Drug Prices

Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) issued a statement today reacting to the administration’s decision to delay implementation of a U.S. Department of Health and Human Services (HHS) policy published at the very end of the Trump administration known as the Rebate Rule.

“CSRxP applauds the Biden administration’s decision to delay this misguided pharma-backed proposal to protect America’s seniors and taxpayers,” said CSRxP executive director Lauren Aronson. “We commend the administration for seeing through Big Pharma’s blame game and making the right call to delay this misguided policy which would do nothing to lower drug prices while also increasing premiums on Medicare Part D beneficiaries, costing taxpayers more than $200 billion and handing drug companies a more than $100 billion bailout.”

“We are also pleased to see the Government Accountability Office (GAO) agree the Rebate Rule was issued in violation of a legally required process for public input,” Aronson continued. “CSRxP looks forward to working with the administration and lawmakers to permanently reverse implementation of this disastrous policy and focus drug pricing efforts instead on market-based solutions to increase transparency, boost competition and hold Big Pharma accountable.”

Get The Facts on the Rebate Rule

Learn more about the misguided Rebate Rule HERE.

Learn more about market-based solutions to hold Big Pharma accountable and lower prescription drug prices HERE.

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.